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1 |  INTRODUCTION
Corneal dystrophy in Friesian horses was described as a 
variant of pellucid marginal degeneration (PMD) in humans. 
Since corneal cross-linking (CXL) has been beneficial in the 
stabilization of PMD, a typical ulcerative corneal lesion with 
secondary bacterial infection in a Friesian horse was success-
fully CXL treated.
Corneal dystrophies are defined as a group of bilateral, 
genetically determined, noninflammatory corneal diseases. 
They can be divided in three groups according to anatomic 
location: epithelial, stromal or endothelial.1,2 In humans, pel-
lucid marginal degeneration (PMD) is a bilateral progressive 
corneal disorder characterized by a noninflammatory ventral 
band of corneal thinning and ectasia.3 It is considered a vari-
ant of keratoconus.4 Corneal ectasia results in astigmatism, 
which leads to impaired vision. Multiple treatment modali-
ties are currently used, including intracorneal rings, contact 
lenses or keratoplasty.5 Corneal thinning can lead to corneal 
perforation which must be treated surgically.6
Corneal dystrophy in Friesian horses is characterized as 
a bilateral symmetric corneal stromal loss without signs of 
inflammation.7 Middle aged and male horses are overrep-
resented.8 No signs of uveitis are typically present unless 
corneal perforation occurs. The disease was suggested to rep-
resent a variant of PMD in a recent publication.7
Optical coherence tomography (OCT) is an important 
noninvasive imaging tool for corneal diseases in human oph-
thalmology and widely used in animal research.9-14 It gen-
erates cross-sectional images providing information with 
resolutions approaching that of histopathology.15 Progression 
of both the initial corneal disease and the healing process fol-
lowing treatment could be visualized very well in our patient 
with this technique.
Corneal cross-linking (CXL) is performed as a min-
imally invasive procedure for stabilization of corneal ec-
tatic disorders and to improve functional visual acuity 
in humans.16-18 In the normal cornea, there are covalent 
bonds between collagen molecules. The process of corneal 
cross-linking increases the number of these bonds by pho-
topolymerization. Riboflavin is applied to the cornea and 
activated by UV-A light (370 nm), which creates covalent 
bonds between protein residues and/or other molecules.19 
As a result, CXL improves corneal stromal resistance 
to enzymatic digestion20-24 and damages multiple tar-
gets within microorganisms, thus eliminating them.25-28 
Corneal cross-linking was proven to be effective against 
bacteria in vitro and in vivo and is widely used in infec-
tious keratitis.29-34 If used to treat infectious keratitis and 
associated corneal stromal degradation, CXL is referred 
to as PACK-CXL, meaning Photo Activated Chromophore 
for Keratitis—Corneal Cross-linking.
31,35,36 Corneal 
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cross-linking was successfully used to stabilize an ulcer-
ative corneal lesion with stromal loss in a Friesian horse in 
this case report.
2 |  MATERIALS AND METHODS
2.1 | Ophthalmic examination
A complete ophthalmic examination including slit 
lamp biomicroscopy (SL-17; Kowa), fluorescein test-
ing (Fluostrip; Contacare Ophthalmics & Diagnostics), 
indirect ophthalmoscopy (HEINE Omega 500, Heine 
Optotechnik GmbH & Co. KG); and tonometry (Tonovet®; 
Icare Finland Oy) was performed during the initial and 
each recheck examination. A detailed examination of the 
corneal lesions was performed with OCT (Envisu R2210 
with 20 mm telecentric anterior segment lens; Bioptigen, 
Leica microsystems).
2.2 | Corneal cross-linking
A 0.1% riboflavin/ 1% hydroxypropyl methylcellulose solu-
tion without dextran (Peschke M®; System Vision SA) was 
applied to the cornea every 1-2 minutes for 20 minutes fol-
lowed by an accelerated CXL treatment (CCL Vet® corneal 
cross-linking system, Peschke Trade GmbH). A total dose of 
irradiation energy (fluence) of 10.8  J/cm2 was delivered to 
the treatment area via two cycles of 45 mW/cm2 UV-A ir-
radiation for 2 minutes. Two drops of riboflavin were applied 
between the cycles. Saturation of the cornea with riboflavin 
and the CXL treatment were both performed with the horse 
standing and sedated.
3 |  CASE DESCRIPTION
A 16-year-old, male castrated, Friesian horse was presented 
to the Ophthalmology section at the Vetsuisse Faculty of the 
University of Zurich because of reported chronic conjuncti-
vitis on the left side and acute bilateral fluorescein-negative 
changes in the cornea with blepharospasm on the left eye. 
The horse had been treated with diclofenac eye drops on both 
eyes once daily for two days.
4 |  CLINICAL FINDINGS AND 
TREATMENT
Both eyes were open with mild mucous discharge. 
Intraocular pressure was 16  mm  Hg in the right eye and 
12  mm  Hg in the left eye. A ventro-temporally located, 
focal, oval gray to white corneal opacification was iden-
tified in both eyes. A fluorescein-negative corneal facet 
of about 7  mm diameter with ±20% stromal loss in the 
center of the facet was detected on the right eye. Optical 
coherence tomography examination revealed a corneal de-
fect with 15% stromal loss and hyperreflective subtending 
stroma, covered by an irregular and centrally thinned but 
intact corneal epithelium (mean stromal thickness of sur-
rounding unaffected area 567 ± 42 µm) (Figure 1A,B). The 
corneal opacity on the left eye was 1 cm in diameter with a 
somewhat irregular fluorescein-negative epithelial surface 
in the center of the lesion. Optical coherence tomography 
examination revealed an intact but hyperreflective epithe-
lium with irregular surface and mildly hyperreflective sub-
tending stroma (Figure 1C,D). Findings were characteristic 
of Friesian corneal dystrophy.7 Due to an improvement in 
comfort observed during the two previous days, the topical 
diclofenac treatment initiated by the referring practitioner 
was continued twice daily on both eyes.
Five days later, the horse returned as an emergency case 
because of moderate blepharospasm and purulent ocular 
discharge on the right eye. The corneal lesion was now 
fluorescein positive with ±20% stromal loss, stromal in-
filtrates were present throughout the ulcerated area and cy-
tology revealed epithelial cells, neutrophils and rod-shaped 
bacteria. Optical coherence tomography demonstrated ep-
ithelial loss, stromal hyperreflectivity and changes in stro-
mal organization. Bacterial culture results were negative. 
The pupil was miotic (Figure 2). Medical treatment was 
changed to topical ofloxacin (Floxal® eye drops, Bausch 
& Lomb Swiss AG), heterologous serum and EDTA 0.33% 
eye drops (compounded, Kantonsapotheke Zurich) every 
three hours, atropine 1% eye drops (Minims® atropine sul-
fate 1.0% w/v eye drops, Bausch & Lomb) twice daily and 
systemic flunixin (Fluniximin® ad us. vet., Dr E. Graeub 
AG) 1 mg/kg intravenously twice daily.
No improvement in clinical signs was observed the fol-
lowing day. Since corneal dystrophy, with typical findings 
before ulceration, was thought to be the underlying cause 
for the corneal infection, corneal cross-linking was per-
formed as described above with the horse in standing se-
dation with detomidine (Medesedan®, Virbac Switzerland 
AG) 10 mcg/kg intravenously. The ulcer stabilized during 
the following two days, presenting without additional stro-
mal loss, a more stable-looking stroma, decreased density 
of infiltrates, progressive epithelization and decrease in 
blepharospasm. Treatment was changed to topical oflox-
acin, serum and EDTA 0.33% eye drops every 6  hours, 
atropine 1% eye drops every other day and oral flunixin 
(Equinixin®, Norbrook Laboratories) 1.1  mg/kg once 
daily. The horse was discharged after 4 days with the topi-
cal therapy described above and oral meloxicam once daily 
(Inflacam®, Virbac Switzerland AG; 0.6 mg/kg).
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The ulcer epithelialized within the three weeks fol-
lowing CXL treatment without additional loss of corneal 
stroma and the frequency of topical serum and EDTA ther-
apy was gradually reduced during this period of time. Oral 
meloxicam was discontinued two weeks after CXL. A stable 
epithelialized corneal scar with 20% stromal loss had devel-
oped on the right eye one month after CXL therapy. Optical 
coherence tomography demonstrated a smooth, intact but 
hyperreflective epithelium with irregular surface and a 
highly disorganized and hyperreflective subtending corneal 
stroma (Figure 3C,D). Three months after CXL therapy a 
slightly elevated vascularized pannus had filled the epithe-
lialized corneal scar site. Optical coherence tomography 
demonstrated a smooth, intact, regular epithelium of nor-
mal reflectivity and an organized, well demarcated, highly 
reflective subtending stroma (Figure 3E,F). The left eye 
was stable during follow-up.
5 |  DISCUSSION
Treatment with corneal cross-linking in combination with 
medical therapy was associated with prevention of progres-
sive corneal stromal loss in a Friesian horse with infectious 
keratitis and underlying corneal dystrophy as presented in 
this case report.
Corneal ectatic disorders in humans are characterized 
as a stromal instability originating from collagen abnor-
malities.19 The etiology of keratoconus is not fully under-
stood, but it can occur as a result of genetic predisposition 
triggered by environmental factors.37 Between 8% and 10% 
of patients have a hereditary component and family his-
tory.37 The pathogenesis may be associated with contact 
lens wear, eye rubbing, Down's syndrome, atopic disease or 
connective tissue disorders like Ehlers-Danlos syndrome, 
Marfan syndrome or Osteogenesis Imperfecta.37,38 The 
F I G U R E  1  A, Picture of the cornea of the right eye (OD) with inconspicuous ventro-temporally located oval corneal opacification 
(arrows). About 20% stromal loss was identified with the slit lamp. B, Correlating OCT image demonstrating an intact epithelium with loss and 
hyperreflectivity of the subtending stroma. C, Picture of the left eye (OS) with a very mild ring-shaped corneal opacification located in the ventro-
temporal region (arrows). D, Superficial hyperreflectivity in an intact epithelium with near normal to mildly hyperreflective subtending stroma 
visible on the correlating OCT image
(A) (B)
(C) (D)
F I G U R E  2  A, Clinical picture of OD at presentation five days later with an epithelial defect in the previously identified area of 20% stromal 
loss and stromal infiltrates throughout the ulcerated area. The pupil was miotic at presentation. B, Correlating OCT image revealing loss of 
epithelium, stromal hyperreflectivity and changes in stromal organization
(A) (B)
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biosynthesis of extracellular matrix components like pro-
teoglycans is altered in the disease, leading to a decrease 
in keratan sulfate chains and an increase in dermatan sul-
fate chains. This change in glycosaminoglycan (GAG) ratio 
weakens the cohesive forces of collagen sheets.39 Changes 
in proteoglycan-GAG composition in the stroma of scarred 
keratoconus corneas were also reported.40 Corneal samples 
of PMD patients contained degenerated collagen fibrils and 
very large proteoglycans.41
A multisystem manifestation of improper collagen for-
mation has been hypothesized as an underlying cause for 
bilateral corneal stromal loss in Friesian horses with cor-
neal dystrophy as well. As mostly male individuals are af-
fected, a simple X-chromosomal inheritance was suggested 
but could not be proven.8 Collagen abnormalities have been 
described in other organs in Friesian horses. For example, 
increased matrix metalloproteinase activity, lysine hydrox-
ylation and elastin cross-linking were found at the site of 
aortic rupture in affected horses.42 Another study described 
disorganized elastin in the aorta of affected animals.43 More 
abundant and abnormal collagen between muscular layers 
was described in Friesian horses with esophageal dysfunc-
tion.44 Results of a recent study indicate a higher rate of 
collagen degradation in the Friesian horse, which could ex-
plain the general predisposition to connective tissue disor-
ders.45 Bacterial infection developed secondary to corneal 
stromal degeneration and disruption of the epithelium in 
the Friesian horse presented in our case report. Previous 
topical diclofenac treatment could have been a contributing 
factor as it is reported to be associated with corneal ulcer-
ation.46 Infected corneal ulcers are a common, painful and 
potentially blinding disease in all species47 usually caused 
by secondary bacterial or fungal infections in horses.47-49 
The inflammatory response to infection activates proteo-
lytic collagen-dissolving enzymes in the corneal stroma re-
sulting in “corneal melting” which can lead to corneal ulcer 
deepening, corneal perforation and loss of vision despite 
aggressive medical therapy.47,50
Corneal perforation appears frequently in Friesian horses 
with corneal dystrophy, even without secondary infections, 
and surgical repair is often needed to save the eye.7 Surgical 
intervention usually necessitates general anesthesia with a 
~1% risk of anesthesia-related death in horses, which is much 
higher than in dogs and cats.51 Additionally, the frequency of 
dehiscence of conjunctival grafts was high in Friesian horses 
with corneal dystrophy (5/9 eyes) with ongoing degener-
ative processes as presumed cause and a second anesthesia 
necessary in three out of five eyes.7 Alternatives to surgical 
interventions under general anesthesia would, therefore, be 
welcome, especially since these patients can represent an in-
creased anesthetic risk as a result of associated cardiovascu-
lar disease.42,43
F I G U R E  3  A, Picture of OD one 
week after CXL. B, The correlating OCT 
image shows a newly formed thin and 
irregular epithelium. C, Picture of OD one 
month after CXL. D, OCT demonstrated 
a smooth, intact but hyperreflective 
epithelium with irregular surface and a 
highly disorganized and hyperreflective 
subtending corneal stroma. E, Picture of 
OD three months after CXL displaying the 
healing process. A vascularized stromal 
scar with intact epithelium is now visible. 
F, Correlating OCT image demonstrating 
an intact and smooth epithelium of 
normal reflectivity and an organized, well 
demarcated, highly reflective subtending 
stroma. A parallel pattern is again visible in 
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Corneal cross-linking has been described as treatment alter-
native for pellucid marginal degeneration in human patients52-54 
and is a cost-effective treatment modality that can be per-
formed on a sedated standing horse,55 provided that the disease 
is detected early when corneal stromal loss is still limited.56 
A minimum corneal thickness of 400 µm to allow sufficient 
absorption of the UV-A radiation in the riboflavin saturated 
stroma is recommended to safely perform CXL and avoid en-
dothelial, lens and retinal damage.19 Historically, single fluence 
protocols delivering 5.4 J/cm2 of energy to the corneal stroma 
have been used for the treatment of keratoconus and bacterial 
keratitis.29,32,57 A high energy double fluence CXL protocol 
(10.8 J/cm2) was used in this case since single fluence proto-
cols have demonstrated somewhat variable effectivity in horses 
with infectious keratitis.55 Also, increasing fluence increases 
treatment effect.58-60 Moderate fluence (7.2 J/cm2) significantly 
increased corneal stromal resistance to enzymatic digestion ex 
vivo compared to corneas cross-linked with routine fluences 
(5.4 J/cm2).59 In addition to that, large CXL fluence increases 
from 5.4 to 27 J/cm2 caused large increases in antibacterial ef-
ficacy. Bacterial killing rates increased from 50% to >90% with 
double fluences of 10.8 J/cm2 and to 100% with triple fluences 
of 16.2 J/cm2 and above.58,60 Increasing corneal stromal resis-
tance to enzymatic digestion and killing of bacteria were both 
desirable treatment effects because of the presumed enzymatic 
corneal stromal degeneration caused by the primary corneal 
dystrophy and secondary infectious keratitis in our patient.47,50
Significant CXL side effects are unlikely to occur with 
a double fluence protocol since topography-guided CXL 
protocols with regional fluences ranging from 7.2 to 15  J/
cm2 have been used for human keratoconus patients without 
detrimental effects.61 Also, no negative effects on the cor-
neal endothelium or retina were reported following the use 
of 15-20 J/cm2 fluences in preclinical studies on nonhuman 
primates and 10-15 J/cm2 fluences in a clinical safety study 
on blind human eyes.62
Optical coherence tomography is a valuable diagnostic 
tool in PMD patients and was helpful to determine epithelial 
integrity and the exact remaining corneal thickness as stromal 
loss was slightly overestimated via slit lamp examination.63,64
The medical ulcer treatment likely contributed to the pos-
itive treatment outcome in the case described here. However, 
ulcer healing was reported to last from six to eight weeks in 
Friesian horses treated for corneal dystrophy,7 which is twice 
the time that the Friesian horse in our report needed for com-
plete reepithelization. However, this might not be a fair com-
parison since only one eye was treated and the disease was 
detected and treated early in our case.
In conclusion, corneal cross-linking seemingly stabilized 
the cornea in the case presented here and should, therefore, 
be considered as treatment option for Friesian horses with 
infectious keratitis and underlying corneal dystrophy.
The efficacy of CXL for stabilization of the corneal stroma 
and prevention of corneal perforation in Friesian horses with 
corneal dystrophy will need to be evaluated in a multicenter 
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